Open AccessSoluble Angiotensin-Converting Enzyme 2: A Potential Inhibitor in Oral and Salivary Coronavirus Infection Therapy
Author(s) -
Attapon Cheepsattayakorn
Publication year - 2022
Publication title -
journal of pulmonology research and reports
Language(s) - English
Resource type - Journals
ISSN - 2754-4761
DOI - 10.47363/jprr/2022(4)127
Subject(s) - saliva , oral mucosa , medicine , transmission (telecommunications) , viral load , covid-19 , oral cavity , virology , debulking , tongue , immunology , disease , virus , pathology , dentistry , electrical engineering , infectious disease (medical specialty) , engineering , ovarian cancer , cancer
A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including ScienDirect, PubMed, Scopus, and ISI Web of Science. The search was applied to the articles that were published between 2004 and early 2022. With strict literature search and screening processes, it yielded 4 articles from 142 articles of initial literature database. In oral cavity, tongue has the highest angiotensin-converting enzyme 2 (ACE 2) expression and lesser amounts in the other oral tissues, oral mucosa, including the gingival tissue. By Pre-incubation with SARS-CoV-2 (COVID-19) RBD, CTB-ACE 2 activity was absolutely inhibited, offering an the description for decreased saliva ACE 2 activity in COVID-19 patients. Through minimizing or debulking virus transmission, SARS-CoV-2 (COVID-19)-trapping proteins proposes an affordable strategy for protecting people from most oral reinfection, whereas newly evolving strains have higher viral load in saliva and greater transmission. Delta variant viral load in a patient is about 1,260 times higher than those infected with previous strains. In conclusion, ACE 2 fusion proteins or chewing gum can be used as the rapid methods of decreasing SARS-CoV-2 (COVID-19) from saliva and oral cavity of the infected patients for minimizing infection and transmission, diagnosis, inhibitors, vaccine development, and therapy of SARS-CoV-2 (COVID-19) disease.